Primary coronary intervention in diabetic octogenarians with acute ST elevation myocardial infarction

Kardiologia Polska

Volumn 65, Issue 10, 2007, Pages 1181-1186

  Sosnowski, Cezary ^a   Janeczko Sosnowska, Ewa ^b   Woźniak, Jacek ^a   Jasiński, Bogdan ^a   Da̧browski, Rafał ^a   Sumiński, Andrzej ^a   Wiernikowski, Andrzej ^a   Ostrzycki, Adam ^a   Szwed, Hanna ^a   Ruzyłło, Witold ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Acute coronary syndrome; Diabetes mellitus; Elderly; Primary coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CONTRAST MEDIUM; GLUCOSE; HEPARIN; INSULIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INSULIN TREATMENT; KIDNEY DISEASE; LOADING DRUG DOSE; MALE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RISK FACTOR; ST SEGMENT ELEVATION; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 36148934589     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
3. Franklin K, Goldberg RJ, Spencer F, et al. GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 2004; 164: 1457-63.
4. Yan RT, Yan AT, Tan M, et al. Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. Am Heart J 2006; 152: 676-83.
5. Bassand JP, Danchin N, Filippatos G, et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 2005; 26: 2733-41.
6. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990; 119: 1262-7.
7. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997; 96: 1761-9.
8. Natali A, Vichi S, Landi P, et al Coronary atherosclerosis in Type II diabetes: angiographic findings and clinical outcome. Diabetologia 2000; 43: 632-41.
9. Sosnowski C, Janeczko-Sosnowska E, Pasierski T, et al. Wpływ cukrzycy typu 2 na miażdżycȩ tȩtnic wieńcowych i obwodowych. Diabetologia Doświadczalna i Kliniczna 2005; 5: 433-8.
10. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
11. Fergus TS, Fazel R, Fang J, et al. Presentation, management, and outcomes of diabetic patients compared to non-diabetic patients admitted for acute coronary syndromes. Heart 2004; 90: 1051-2.
12. Stone GW, Grines CL, Cox DA, et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-66.
13. Stuckey TD, Stone GW, Cox DA, et al. CADILLAC Investigators. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol 2005; 95: 1-7.
14. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-9.
15. Hsu LF, Mak KH, Lau KW, et al. Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis. Heart 2002; 88: 260-5.
16. Aguilar D, Solomon SD, Køber L, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004; 110: 1572-8.
17. Ishihara M, Inoue I, Kawagoe T, et al. Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. Am Heart J 2003; 146: 674-8.
18. West NE, Ruygrok PN, Disco CM, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004; 109: 867-73.
19. Marfella R, Siniscalchi M, Esposito K, et al. Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care 2003; 26: 3129-35.